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Abstract
Background: Intracellular proteases constitute a class of promising drug discovery targets. Methods for high throughput
screening against these targets are generally limited to in vitro biochemical assays that can suffer many technical
limitations, as well as failing to capture the biological context of proteases within the cellular pathways that lead to their
activation.
Methods & Findings: We describe here a versatile system for reconstituting protease activation networks in yeast and
assaying the activity of these pathways using a cleavable transcription factor substrate in conjunction with reporter gene
read-outs. The utility of these versatile assay components and their application for screening strategies was validated for all
ten human Caspases, a family of intracellular proteases involved in cell death and inflammation, including implementation
of assays for high throughput screening (HTS) of chemical libraries and functional screening of cDNA libraries. The versatility
of the technology was also demonstrated for human autophagins, cysteine proteases involved in autophagy.
Conclusions: Altogether, the yeast-based systems described here for monitoring activity of ectopically expressed
mammalian proteases provide a fascile platform for functional genomics and chemical library screening.
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Introduction
Proteolytic processing of proteins is an irreversible post-
translational modification of importance for a wide-variety of
biological processes, including cell division, cell death, cell
differentiation, innate immunity, host-pathogen interactions, and
intracellular protein sorting and trafficking. Consequently, prote-
ases have emerged as promising targets for drug discovery for a
wide variety of human diseases, including cancer, neurodegener-
ation, ischemic diseases, inflammation, and infectious diseases.
Development of high throughput screening (HTS) assays using
purified proteases can be relatively straightforward or it can be
quite challenging, particularly when multi-component systems are
required to achieve protease activation. Also, due to similarity of
the active sites of some groups of proteases, selectivity of chemical
inhibitors can be difficult if not impossible to achieve, highlighting
the need for alternative screening methods for identifying
compounds that target upstream activators of proteases rather
than directly inhibiting the protease of interest.
Caspases represent an excellent example of a family of
intracellular endopeptidases for which novel HTS tools are
desired. Caspases are cysteine proteases that are conversed
throughout the animal kingdom. The human genome contains
at least 10 genes encoding Caspases (reviewed in [1]). These
proteases often collaborate in complex proteolytic networks that
encompass upstream initiators and downstream efforts, where
upstream members of the Caspase family cleave and activate
downstream members. Upstream initiator Caspases become
activated through protein interactions involving assembly of
multi-protein complexes (reviewed in [2,3]), which are often
difficult to reconstitute in vitro. The substrates cleaved by active
Caspases are responsible for apoptotic cell death and for cytokine-
mediated inflammation, thus making these proteases attractive
targets for drug discovery for a wide variety of degenerative
diseases, ischemic disease.
Autophagy is an evolutionarily conserved process for cataboliz-
ing organelles and macromolecules during times of nutrient
insufficiency for the purpose of generating substrates for
maintaining ATP production (reviewed in [4]). Autophagy is
recognized as a cell survival mechanism in many contexts of
relevance to human physiology and disease, though it also may
contribute to non-apoptotic cell death under some circumstances
PLoS ONE | www.plosone.org 1 October 2009 | Volume 4 | Issue 10 | e7655[5]. Autophagins are intracellular cysteine proteases required for
autophagy [6]. The human genome contains four genes encoding
autophagy proteases, which include ATG4A, ATG4B, ATG4C,
and ATG4D [7].
We created yeast-based cellular systems that permit facile
expression of proteases and protease-activating proteins in
combinations that reconstitute entire mammalian pathways in
these simple eukaryotes. Among the assay methods integrated into
the yeast system are cleavable reporter gene activators, in which
protease-mediated cleavage activates a transcription factor. We
demonstrate here the utility of this approach for caspases and
autophagins. Applications of this technology to high throughput
chemical library screening and to cDNA library screening
demonstrate its broad applicability.
Results
Development and testing of a cleavable transcription
factor and reporter gene system for assaying protease
activity in living yeast
We devised a reporter gene system for monitoring protease
activity in living yeast, modeled after prior reports that used the
same concept [8,9]. For this purpose, a Type I transmembrane
receptor (CD95; Fas) was expressed such that most of its cytosolic
domain was replaced by a chimeric transcription factor comprised
of the DNA-binding domain of LexA and the transactivation
domain of B42. Between Fas and the chimeric transcription factor
(LexA-B42) we cloned various numbers of tetrapeptide sequences
known to be recognized and cleaved by various members of the
Caspase family. As a control, constructs were prepared in which
the sessile aspartic acid within the tetrapeptide sequence was
replaced with glycine (Figure 1A, B). These reporter constructs
were expressed from plasmids in autotrophic yeast mutant strains
EGY48 (MATa trp1, his3, ura3, lexA6op-LEU2) or EGY191 (MATa
trp1, his3, ura3, lexA2op-LEU2), containing stably integrated LEU2
(allows grown on leucine-deficient media only when the operator is
activated by the transcriptional activator, LexA-B42) and episomal
lacZ (produces b-galactosidase) reporter gene under control of
promoters containing 1, 2, 4, 6 or 8 copies of the LexA-binding
operator [10].
Caspases are initially produced as inactive zymogens, which
typically undergo proteolytic processing to produce active enzymes
composed in most cases of tetrameric assemblies with two large
(,20 kDa) and two small (,10 kDa) subunits. Simply over-
expressing Caspases in yeast is sufficient to lead to their activation
in many cases [11,12,13,14], presumably because upstream
initiator Caspases are typically activated by dimerization and also
because many Caspases are capable of cleaving and activating
their zymogen forms, constituting a feed-forward mechanism for
amplifying protease signaling (reviewed in [15]). Moreover,
expressing high levels of some Caspases results in killing of yeast
or growth suppression [11,12,13,14,16], thus interfering with use
of a cleavable transcription factor and reporter gene strategy for
monitoring changes in Caspase activity. The key to applying
reporter gene-based systems for evaluating Caspase activity in
yeast thus is to carefully titrate levels of expression of these
proteases so that expression is sufficiently high to achieve
activation but insufficient to kill yeast or impair their growth.
To accomplish this goal, we empirically evaluated several yeast
promoters and also produced attenuated versions of some
promoters to titrate Caspase expression to appropriate levels.
We expressed full-length Caspases-1, 2, 3, 4, 5, 6, 7, and 9 from
high copy-number plasmids using either ADH or TEF promoters,
which are constitutive promoters with moderate to strong activity.
The levels of Caspase expression afforded by the ADH and TEF
promoters were sufficient to achieve ‘spontaneous’’ activation of
these over-expressed proteases, but insufficient to kill yeast or
impair their growth. For Caspases-8 and 10, however, we co-
expressed a small amount of the full-length (zymogen) proteins
using the CYC promote (a constitutive promoter with relatively
weak activity) together with a large amount of the upstream
activator, FADD (an adapter protein that contains a Death
Effector Domain (DED) that binds the DEDs found in the
prodomains of Caspase-8 and -10 [17], because large amounts of
active Caspases-8 or -10 inhibited the yeast cell growth
significantly, consistent with prior reports [18,19]. Using a DLEU2
yeast strain containing LEU2 and lacZ reporter genes, active
Caspases were co-expressed with cleavable transcription factors
containing various tetrapeptide target sequences. Pilot experiments
with different numbers of cleavage sites in the membrane-tethered
transcription factor (n=126) suggested that a single tetra-peptide
Caspase cleavable sequence yields satisfactory results. We em-
pirically adjusted variables such as the strengths of the yeast
promoters driving expression of Caspases and the Fas-LexA-B42
cleavable fusion proteins and the type of DNA replication origin in
the plasmids (high copy versus low copy) to optimize signal:noise
ratio, so that background (spontaneous) activation of the LEU2
and lacZ reporter genes was minimal (not shown), while also
titrating the number of lexA operators in the reporter genes to
ensure a signal well above background.
When plated on complete medium, all leu2 transformants grew,
as expected (Figure 1C). However, a selective pattern of growth was
observed for yeast transformants when they were plated on leucine-
deficientmediumtotest activityoftheLexAop-LEU2reportergene,
along with X-gal substrate to colorimetrically detect the presence of
b-galactosidase activity. In yeast containing the WEHG control
sequence, which lacks the sessile aspartic acid required for
Caspase cleavage, none of the yeast transformants grew or showed
b-galactosidase-positivity, includingCaspase-1through Caspase-10.
Yeast in which the Fas-LexA-B42 fusion protein contains the
WEHD tetrapeptide sequence grew on leucine-deficient media and
showed b-galactosidase-positivity when co-expressed with active
Caspases-1, 4, and 5, but not Caspases-2, 3, 6, 7, 8, 9, or 10,
perfectly matching predictions of prior studies in which the optimal
tetrapeptide substrate sequences were determined for these human
Caspases [20]. Similarly, yeast containing the DEVD linker in the
Fas-LexA-B42 fusion protein grew on leucine-deficient media and
showed b-galactosidase-positivity when co-expressed with active
Caspase-3 or Caspase-7, but not Caspases-1, 4, 5, 6, 8, 9, or 10,
showing striking preferentiality among Caspases for cleavage of this
reporter protein. Caspase-2 also cleaved the DEVD-containing
reporter protein, which differs only slightly from the reported
optimal substrate sequence of DEHD and was reported to be
second-most efficiently cleaved tetrapeptide sequence for this
protease [20]. The DEHD substrate (designed for Caspase-2)
produced results very similar to DEVD, showing activation by
Caspases-2, -3, and -7, consistent with prior substrate specificity
experiments suggesting that the P2 position where H was placed is
the most flexible residue for Caspases-3 and -7 substrates [20]. The
other tetrapeptide sequences optimized for Caspase-6 (TEVD),
Caspases-8/10 (LETD) and Caspase-9 (LEHD) resulted in less
specific patterns of reporter protein activation, but nevertheless
showed selectivity. For example, the ‘‘inflammatory’’ Caspases
(Caspases-1, 4, and 5) did not activate the Caspase-6 substrate
(TEVD). Also, the downstream effector Caspases (Caspases-3, 6, 7)
did not activate the reporter proteins containing tetratpeptide
sequences optimized for upstream initiator Caspases (LETD,
Caspases-8/10; LEHD, Caspase-9). In contrast, the lacZ reporter
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PLoS ONE | www.plosone.org 2 October 2009 | Volume 4 | Issue 10 | e7655Figure 1. A genetic system for monitoring Caspase-1 activity in yeast cells. (A) Engineered yeast were created that express a type-1
transmembrane protein (Fas-d-S1-TA) in which the Fas devoid of the death domain (Fas-d) is followed by a Caspase-1 target site (S1-WEHD), and a
transcriptional activator (TA-consisting of LexA DNA binding domain and B42 activation domain). lexA operators are located upstream of lacZ (2
operators) and LEU2 (6 operators) reporter genes, respectively. The cells expressing 6op-LEU2/2op-lacZ/TEF-Fas-d-S1-TA stimulate Caspase-1 activity
reporter, becauseexpression ofactiveCaspase-1(over-expressinga full-length pro-Caspase-1construct)results inFas-d-S1-TAcleavageatthe Caspase-1
target site (S1), releasing the transcriptional activator (TA), which enters the nucleus and activates lacZ and LEU2 reporter gene transcription. (B)A
version of Fas-d-S1-TA in which the P1 aspartate is changed to glycine (Fas-d-G1-TA) cannot be cleaved by active Caspase-1. The cells expressing 6op-
LEU2/2op-lacZ/TEF-Fas-d-G1-TAinwhichtheglycinesubstitutionisfoundserveasfalse-positivereportersformoleculesthatactivatelacZandLEU2gene
expressions independent of cleavage at the Caspase-1 target site. (C) Substrate specifities of the caspases expressed in yeast. Plasmids encoding various
cleavabletranscription factorsubstrates, harboring different tetrapeptide cleavagesequences optimized forspecificCaspases (Fas-d-S1-TA, Fas-d-S2-TA,
Fas-d-S3-TA, Fas-d-S6-TA, Fas-d-S8-TA, and Fas-d-S9-TA) were created by substituting the Caspase-1 cleavage site (S1-WEHD) with the Caspase-2
cleavage site (S2-DEHD), the Caspase-3 cleavage site (S3-DEVD), the Caspase-6 cleavage site (S6-TEVD), the Caspase-8/Caspase-10 cleavage site (S8-
LETD), and the Caspase-9 cleavage site (S9-LEHD), respectively, and were expressed with the lacZ and LEU2 reporter genes. A construct encoding a Fas-
LexA/B42 transcription factor containing a pseudo-site (G1) with the non-cleavable sequence WEHG was also generated. The resultant yeast strains
EGY48, expressing 6op-LEU2/2op-lacZ/TEF-Fas-d-G1-TA, 6op-LEU2/2op-lacZ/TEF-Fas-d-S1-TA, 6op-LEU2/2op-lacZ/TEF-Fas-d-S2-TA, 6op-LEU2/2op-lacZ/
TEF-Fas-d-S3-TA, 6op-LEU2/2op-lacZ/TEF-Fas-d-S6-TA, 6op-LEU2/2op-lacZ/TEF-Fas-d-S8-TA, or 6op-LEU2/2op-lacZ/TEF-Fas-d-S9-TA, were transformed
with Caspase expression plasmids. Substrate specificities were determined for the ten Caspases (C1–C10). If cells express the active Caspases with the
suitable cleavage sites, the cells can grow in the selection medium (without leucine) and they hydrolyze X-gal to become blue. Expression of the
Caspases (p424-ADH-Caspase1-FLAG, p424-ADH-HA-Caspase2, p424-ADH-Caspase3, p424-TEF-Caspase4, p424-ADH-Caspase5, p424-TEF-HA-Caspase6,
p424-ADH-Caspase7, p424-CYC1-Caspase8-HA/TEF-HA-FADD, p424-ADH-HA-Caspase9-FLAG, and p424-CYC1-Caspase10-FLAG/TEF-HA-FADD) had no
effects on the cell growth when plated on regulate (leucine-containing) medium.
doi:10.1371/journal.pone.0007655.g001
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constructs in which the aspartic acid in position P1 of the cleavable
linker was converted to glycine or replacing vectors encoding wild-
type Caspases with mutants in which the active site cysteine was
changed to glycine or alanine (Figure S1). Taken together, these data
demonstrate the performance of a one-component cleavable
reporter gene system for measuring activity of all 10 human
Caspases in yeast.
We have employed this system for screening human cDNA
libraries expressed from yeast plasmids, where the cleavable Fas-
LexA-B42 fusion protein was expressed without a Caspase and
cDNA libraries were screened for proteases that activate the
reporter gene (Figures S2-S4). The libraries employed here were
constructed by directional cloning into a high copy-number yeast
plasmid containing GAL1 or ADH promoters (strong and
moderate strength, respectively) for driving cDNA expression.
Using the WEHD-containing reporter protein, we obtained eleven
cDNAs that confirmed positive on repeated testing, including five
that encoded Caspase-1 and six encoding Caspase-4 (Figures S2 and
S4). Using the DEVD-containing reporter, we obtained twelve
clones that confirmed positive, including three that encoded
Caspase-3 and nine encoding Caspase-7 (Figures S3 and S4). These
cDNA library screening results further validate the cleavable
reporter system.
Development of 2-component systems demonstrating
function of Caspase activators in yeast
Next, we attempted to develop 2-component systems for
assaying Caspase activity in yeast, in which the inactive proforms
of the Caspases were co-expressed with various activator proteins
and in which the Caspases were expressed from weak promoters to
achieve levels of the zymogens that avoid ‘‘spontaneous’’
activation. Figure 2 depicts the concept for Caspase-1, showing
its preferred substrate WEHD. Among the 2-component systems
interrogated were combinations of upstream initiator Caspases co-
expressed with known activators, including: (1) pro-Caspase-1 plus
Asc; (2) pro-Caspase-2 plus RAIDD; (3) pro-Caspase-9 plus a gain-
of-function mutant of Apaf1; (4) pro-Caspase-8 plus FADD; and
(5) pro-Caspase-10 plus FADD. In each of these cases, the
upstream initiator Caspase, contains a N-terminal pro-domain
(either CARD or DED) that binds a compatible CARD or DED in
the activator protein. We also tested 2-component systems
involving an upstream and downstream protease. For example,
Caspase-9 is a direct upstream activator of downstream proteases,
Caspases-3 and -7 [21]. We therefore over-expressed active
Caspase-9 (high level expression) in combination with the inactive
proforms of Caspase-3 or -7 (expressed at low levels) (Figures 2G,
2H, S5). In each case, an appropriate cleavable reporter protein
was co-expressed with the 2-component systems in yeast
containing LEU2 and lacZ reporter genes. For all pair-wise
combinations of pro-Caspase and upstream activator, we ex-
pressed the pro-Caspase at relatively low levels using a low-copy
plasmid containing CEN/ARS (1 to 2 copies per cell) and using
weak to moderate strength promoters (such as CYC1, and
DGPD1), and the upstream activator at high levels using 2m
plasmid origin-containing plasmids (20 to 50 copies per cell) with
relatively strong promoters (TEF or ADH). For each pair of pro-
Caspase and upstream activator, we empirically adjusted the
number of lexA operators driving the LEU2 or lacZ reporter genes
to achieve an acceptable signal:noise ratio. For example, for the
combination of pro-Caspase-1 and Asc, we determined that 2 lexA
operators for LEU2 were superior to 4 or 6 operators when using
DTEF1-Caspase1-FLAG to express pro-Caspase-1 (Figure 2), and
that 6 lexA operators for LEU2 were superior to 2 or 4 operators
when using DTEF3-Caspase1-FLAG to express pro-Caspase-1
(Figures S6A and S7).
Successful activation of the cleavable reporter protein was
achieved for each 2-component system (Figure 2). Expression of
either the pro-Caspase alone or the upstream activator alone failed
to result in activation of the LEU2 and lacZ reporter genes, as
determined by ability to grow on leucine-deficient plates and
b-galactosidase-positivity, confirming that both components are
necessary for activating the reporter proteins. Expressing Caspases
in which the active site cysteine was mutated to glycine or alanine
failed to activate the cleavable reporter (Figures S1, S5, and S6).
Moreover, pairing pro-Caspases with the wrong activators (e.g.
Apaf1*+pro-Caspase-8; Asc+pro-Caspase-9) also failed to activate
the reporters (Figure S7). Taken together, these data demonstrate
the utility of yeast-based protease screening using 2 component
systems.
Development of a 3-component system – mammalian
protease activating pathways reconstituted in yeast
Having developed prototypical 2-component systems, we
attempted to increase the complexity of reconstituted Caspase-
activating systems in yeast, moving to a 3-component network.
Two different mammalian Caspase-activating networks were
explored. In the first, we attempted to recapitulate the proximal
portion of the extrinsic pathway (so-called ‘‘death inducing
signaling complex’’ [DISC]), expressing (1) death domain (DD)-
containing TNF-family death receptor, Fas [CD95]; (2) bipartite
adapter protein FADD, which contains DD and DED; and (3) the
proform of a DED-containing protease, either Caspase-8 or
Caspase-10, along with (4) a cleavable reporter protein containing
the Caspase-8/10 substrate tetrapeptide LETD. Two strategies for
reconstituting the Fas/FADD/pro-Caspase-8 network in yeast
were compared. First, we tried expressing the bridging adapter
protein FADD at low levels using a constitutive but weak promoter
such that the amount of FADD was inadequate to achieve pro-
Caspase-8 activation in the absence of Fas. For that system, Fas
was expressed at high levels so that it can oligomerize with itself
without requiring Fas Ligand (Figure 3A). By empirically
comparing different strength promoters for driving expression of
the 3 components and adjusting the number of lexA operators in
the promoters of the LEU2 and lacZ reporter genes, we arrived at
conditions that produced the desired result for the approach
whereby low levels of constitutive FADD were complemented by
expression of Fas (Figure 3C, 3D, S8). Second, we expressed low
levels of either pro-Caspase-8 or pro-Caspse-10 with high levels of
adapter protein FADD (Figure 3B), adding expression plasmids
encoding death receptors such as Fas (CD95) or DR5 (TRAIL-R2)
to this system. However, high FADD was sufficient to activate
Caspase-8 and -10, with addition of death receptors only modestly
further increasing reporter gene activity (Figures 3E, F).
Another 3 component Caspase-activating network was similarly
created for NLR-family proteins, using variations on the same
approach. NLRs constitute a family of signaling proteins involved
in innate immunity, several of which activate pro-inflammatory
Caspases (reviewed in [22]). NLRs are activated by pathogen-
derived ligands via leucine-rich repeat (LRR) domains that auto-
inhibit these proteins in the absence of ligand, controlling
oligomerization of these proteins that form multiprotein complexes
termed ‘‘inflammasomes’’ [23]. We attempted to reconstitute in
yeast the NLRP1 (NALP1) and NLRP3 (NALP3) inflammasome
comprising 3-component systems including: (1) the CARD-
containing protease, pro-Caspase-1; (2) the bipartite adapter Asc,
which contains CARD and PYD domains; and (3) the NLR-family
protein NLRP1/NALP1 (which contains PYD and CARD
Yeast-Based Protease Technlgys
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gain-of-function mutants of NLRP1 and NLRP3 that are
constitutively active without requiring a bacterial ligand to induce
their oligomerization by virtue of deletion of the auto-inhibitory
LRRs [23]. For this system, the reporter protein contained the
Caspase-1 cleavage sequence, WEHD (Figure 4). We then
expressed pro-Caspase-1 and adapter protein Asc in yeast under
constitutive weak promoters, such that the amount of Asc
produced was insufficient to activate pro-Caspase-1 in the absence
of other cofactors. The gain of function mutants, NLRP1(DLRR)
and NLRP3(DLRR) were expressed under control of either strong
inducible (GAL1) or constitutive (TEF) promoters. Upon
NLRP1(DLRR) expression, the reporter genes became activated.
Exclusion of any of the 3 components of this system (NLRP1, Asc,
or pro-Caspase-1) prevented the reporter gene activation (not
shown). Substituting the WEHD-containing cleavable reporter
construct with non-cleavable WEHG and substituting wild-type
Caspase-1 with mutant Caspase-1 in which the active site cysteine
was ablated failed to result in activation of the LEU2 or lacZ
reporter genes (Figure 4C and not shown). We conclude therefore
that NLRP1DLRR and NLRP3DLRR can activate pro-Caspase-1
in yeast in an Asc-dependent manner, thus demonstrating
reconstitution in yeast of another 3-component system for Caspase
activation.
Having developed 3-component systems for Caspase activation,
we next exploited this technology for screening cDNA expression
libraries. Several strategies were successfully employed to explore
the diversity of applications using the Fas/FADD/Caspase-8
system (reconstituted DISC). For example, cDNA cloning
experiments were performed where we omitted the plasmid
Figure 2. Schematic representation of a 2-component system for caspase1 activators in yeast cells. (A) The zymogen (inactive) pro-
caspase-1protein isexpressedinyeast,withthecleavablereporter containingtheS1site(WEHD), byregulatingtheexpressionlevel(p413-TEF-Fas-d-S1-
TA/DTEF1-Caspase1-FLAG)intheyeastcell(EGY191expressing2op-LEU2/2op-lacZ).ThereportergenesaresilentintheabsenceofAsc.Co-expressionof
Asc athigh levelsfrom p424-TEF-HA-Asc activatesCaspase-1, resultingin S1 site cleavage, releasingthe transcription factor from themembraneto enter
the nucleus and activate reporter genes. Co-expression of Asc at high levels from p424-TEF-HA-Asc activates Caspase1, resulting in S1 site cleavage, and
thetranscription factor isreleased from themembranetoenter thenucleusandactivatereporter genes. (B) Yeast transformantswere plated onleucine-
deficient medium containing X-gal. For controls, the ‘‘empty’’ version of the plasmid was always introduced so that cells were subjected to identical
selection conditions. The recipient yeast strain EGY191 containing 2op-LEU2/2op-lacZ with substrate plasmid TEF-Fas-d-S1-TA, with or without a gene
encoding pro-Caspase-1 (DTEF1-Caspase1-FLAG) were transformed with p424-TEF-HA-Asc or empty vector (-). Only the combination of Caspase-1 plus
Asc resulted in reporter gene activation, indicating that Asc itself did not cut the S1 site. (C) Experiments were performed as above, except the recipient
yeast strain EGY48 containing 6op-LEU2/2op-lacZ with substrate plasmid DTEF2-Fas-d-S2-TA, with or without a gene encoding pro-Caspase-2 (DGPD1-
HA-Caspase2-FLAG), was transformed with p424-TEF-HA-RAIDD or empty vector (-). (D) The recipient yeast strain EGY48 containing 6op-LEU2/2op-lacZ
with substrate plasmid GPD-Fas-d-S8-TA, with or without a gene encoding pro-Caspase-8 (CYC1-Caspase8-HA), was transformed with p424-TEF-HA-
FADD or empty vector (-). (E) The recipient yeast EGY48 containing 6op-LEU2/2op-lacZ with substrate plasmid TEF-Fas-d-S9-TA, with or without a gene
encodingpro-Caspase-9 (TEF-HA-Caspase9),was transformedwithp424-TEF-HA-Apaf*expressinganactivemutantofApaf-1oremptyvector (-).(F) The
recipient yeast strain EGY48 containing 6op-LEU2/2op-lacZ with substrate plasmid GPD-Fas-d-S8-TA, with or without a gene encoding pro-Caspase-10
(ADH-Caspase10-FLAG), was transformed with p424-TEF-HA-FADD or empty vector (-). (G, H) The recipient yeast EGY191 containing 2op-LEU2/2op-lacZ
with substrate plasmid DTEF3-Fas-d-S3-7-TA, with or without genes encoding pro-Caspase-3 (DCYC2-Caspase3) or the recipient yeast EGY48 containing
6op-LEU2/2op-lacZ with substrate plasmid TEF-Fas-d-S3-7-TA, with or without genes encoding pro-Caspase-7 (CYC1-Caspase7), was transformed with
p424-ADH-HA-Caspase-9-FLAG or empty vector (-).
doi:10.1371/journal.pone.0007655.g002
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PLoS ONE | www.plosone.org 5 October 2009 | Volume 4 | Issue 10 | e7655Figure 3. 3-component systems for Caspase-8 activation in yeast. The zymogen pro-Caspase-8 is expressed (from CYC1-promoters) with
substrate containing LETD cleavage element S8 (from plasmid p413-TEF-Fas-d-S8-TA) in the yeast EGY48 expressing 6op-LEU2.( A) A small amount of
FADD is also expressed from DADH1 promoter on a low-copy plasmid without activating the Caspase-8. Fas is expressed at high levels from ADH
promoter on a high copy plasmid. (B) FADD and Fas are both expressed at high levels from TEF and ADH promoters, respectively, from high copy
plasmids. (C,D) To validate the system from (A) for cloning cDNAs that activate Caspase-8 or -10 in a FADD-dependent manner (the death receptor
cloning system), we established yeast transformants expressing Caspase-8 or -10, with low levels of FADD or corresponding empty vectors (-). Then, the
cells (FADD/Caspase-8 or -10) were transformed with a Fas-expressing vector (p424-ADH-Fas) or the vector only (-). The yeast transformants included
EGY48-6op-LEU2/2op-lacZ/TEF-Fas-d-S8(LETD)-TA/CYC1-Caspase8-HA (C) and EGY48-6op-LEU2/2op-lacZ/GPD-Fas-d-S8(LETD)-TA/CYC1-Caspase10-
FLAG (D), without (-) or with a small amount of FADD, and were transformed with the a Fas-expressing vector or the empty vector (-). (E,F)T ot e s t
the system from (B), The yeast transformants included EGY48-6op-LEU/2op-lacZ/TEF-Fas-d-S8 (LETD)-TA/CYC1-Caspase8-HA (E), and EGY48-6op-LEU2/
2op-lacZ/GPD-Fas-d-S8(LETD)-TA/CYC1-Caspase10-FLAG (F) without (-) or with large amounts of Fas or DR5, and were transformed with the a FADD-
expressing vector in a large amount under TEF prompter or the empty vector (-). (G–I) Examples of cDNA cloning results. Yeast strain EGY48 containing
6op-LEU2 and 2op-lacZ reporter genes and expressing the LETD-containing substrate (expressed from pTEF-Fas-d-S8-TA) with or without pro-Caspase-8
(CYC1-Caspase8-HA), and/or FADD (DADH1-FADD). Cells were subsequently transformed with various cDNA libraries (Figs. S9-S11) and clones that
activated the reporter genes were characterized by recovery of cDNA library plasmids and retransformation into yeast expressing FADD and pro-
Caspase-8(G), pro-Caspase-8 without FADD (H), or neither (I). Among the positive clones were #XA514 (n=13) encoding a fragment of DR4(G
210-E
468),
#XA512(n=15)encodingafragmentofDR5(A
43-S
411), #XD108(n=8)encodinga fragmentofDR5(Y
99-S
411),and#XD422(n=3)encodingafragment
of DR5(A
192-S
411), and#XD402(n=7) encoding a fragmentof DR5(V
124-S
440), all ofwhich activated thelacZ reporter genein cellscontaining FADD and
Caspase-8 (G) but not in cells lacking FADD (H)o rb o t h( I). Also obtained were cDNAs #XD103 encoding a fragment of Caspase-8 (M
1-R
233), #X8716
encoding a full-length FLIPL, and #XA411 encoding a full-length Caspase-2. Assays were performed in duplicate, growing cells for 4 days on plates.
doi:10.1371/journal.pone.0007655.g003
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levels), Caspase-8 (low levels), and the cleavable reporter, then
screened cDNA libraries prepared in yeast expression plasmids with
moderate strength promoters (typically ADH promoters), searching
for cDNA clones encoding proteins that restored activation of the
cleavable reporter gene containing the LETD target sequence. In
this application, the yeast cell line, EGY48-6op-LEU2/2op-lacZ/
GPD-Fas-d-S8/10(LETD)-TA/CYC1-Caspase8-HA/DADH1-
FADD was used screen to cDNA libraries in search of clones
encoding death receptors that activate Caspase-8 in a FADD-
dependent manner. From a screen of 1.7610
6 cDNAs from a
HepG2 hepatocellular library, 28 of 40 positive clones tested
encoded DR4 (TRAIL Receptor-1) or DR5 (TRAIL Receptor-2)
(Figure 3E–G and supplemental Figure S9), members of the TNF-
family of death receptors that are known to activate Caspase-8 via
FADD[24,25,26,27]. These DR4and DR5-encoding cDNA clones
failed to restore reporter gene activation when FADD was omitted,
showing their dependence on this adapter protein for inducing
activation of Caspase-8 (Figure 3E, F). A second independent
screening of the same HepG2 library, plating 1.2610
6 clones,
resulted in 25 positive colonies, of which 8 encoding DR5
(Figure 3E–G and supplemental Figure S9). Also, screening 7.5610
5
clones from a human liver cDNA expression library resulted in 18
positives, of which 10 encoded DR5 (Figure 3E–G and supplemental
Figure S10). In another cDNA library screening experiment, 5610
5
clones from a HeLa cervical carcinoma cDNA library were
screened, resulting in 19 positives, of which 7 encoded a splice-
variant of Caspase-8. This cDNA clone activated the reporter gene
independently of FADD (Figure 3H) but interestingly not when
eliminating Caspase-8 (Figure 3I), thus illustrating how the
heirarchical functions within pathways of cDNA hits can be readily
deconvoluted by omission of elements of the 3-component system.
Similar examples of cDNA clones encoding downstream activators
of the Fas/FADD/Caspase-8 pathway were found in a screen of
2.2.610
6 clones from a HEK293 renal epithelial cell line library,
which resulted 16 positive clones, of which 2 encoded c-FLIP
(Figure 3G, S11), a Caspase-8-like protein that is known to activate
Caspase-8 in some contexts [28], and 9 clones encoded Caspase-2
(Figure 3G, S11). The c-FLIP cDNA activated the cleavable
reporter independently of FADD but required Caspase-8
Figure 4. Yeast assay for NLRs. (A) Yeast strain EGY48 containing 6op-LEU2/2op-lacZ expressing pro-Caspase-1 (driven by DTEF3 promoter, which
expresses at low levels) with membrane tethered transcription factor substrate containing WEHD peptide linker (S1 substrate) were transformed with
plasmids encoding adapter protein Asc (expressed at low levels from a CYC promoter) and upstream activators either NLRP1DLRR or NLRP3DLRR
(expressed at high levels from TEF or GAL1 promoters). When Caspase-1 is activated via the combination of Asc and NLRP1 or NLRP3, the reporter is
cleaved, releasing the chimeric LexA/B42 transcription factor to leave the membrane and enter the nucleus, where it induces expression of LEU2 and
lacZ genes. (B) EGY48 cells (6op-LEU2, 2op-lacZ) were transformed with plasmids encoding the S1 substrate, pro-Caspase-1 (C1) expressed from
DTEF3 promoter, Asc (low) from CYC promoter, and NLRP3DLRR from TEF promoter. Control transformants received the corresponding empty
plasmids (-). Cells were grown for 2 days on leucine deficient plates containing X-gal and galactose (to induce NLRP3DLRR expression). (C) The EGY48
recipient (6op-LEU2, 2op-lacZ) yeast cell strain contained plasmids encoding substrates with either the WEHD tetrapeptide cleavable linker (S1
substrate expressed from TEF-Fas-d-S1(WEHD)-TA transcriptional unit) or WEHG non-cleavable substrate (G1 substrate expressed from TEF-Fas-d-
G1(WEHG)-TA) in plasmids encoding either wild-type (‘‘C1/WT’’) or Cys285 mutated Caspase-1 (‘‘C1/C
285RG
285’’) (expressed from DTEF3-Caspase-1-
FLAG or DTEF3-Caspase-1(C
285RG
285)-FLAG transcriptional units). Cells were transformed with the plasmids expressing a small amount of Asc (CYC-
Asc), a large amount of Asc (TEF-Asc), a small amount of NLRP1DLRR (CYC-NLRP1), a large amount of NLRP1DLRR (TEF-NLRP1), various combinations,
or empty vectors (-). Yeast transformants were plated on leucine-deficient medium containing X-gal. The large amount of Asc (expressed from TEF
promoter) activated Caspase-1 by itself. NLRP1DLRR was unable to activate Caspase-1 by itself, albeit expressed at high levels (confirmed by
immunoblotting [not shown]). NLRP1DLRR activated pro-Caspase-1 in the presence of a small amount of Asc, under conditions where the amount of
Asc expressed (from CYC promoter) was insufficient to independently activate Caspase-1.
doi:10.1371/journal.pone.0007655.g004
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activated the reporter independently of both FADD and Caspase-8
(Figure 3H, I), suggesting it directly cleaves the reporter protein
containing the LETD sequence. In this regard, while the preferred
cleavage sequence for Caspase-2 has been reported as DEHD, our
comparisons of Caspase-2 on various cleavable reporters showed
that LETD isalso a substrate(Figure 1,S8),consistentwithresultsof
peptidelibrary screensinwhichLat the P4 position was shown tobe
cleaved by Caspase-2 with ,40% the efficiency as D [20]. In
another example of how this 3-component system can be employed
for functional cloning, we expressed low levels pro-Caspase-10 and
high levels of Fas, then screened cDNA libraries to clone adaptor
molecules that link Fas to Caspase-10 (Figures S12-S15). The yeast
cell line EGY48-6op-LEU2/2op-lacZ/GPD-Fas-d-S8/10(LETD)-
TA/CYC1-Caspase10-FLAG/ADH-FasfailedtoactivateCaspase-
10 in the absence of FADD, as monitored by activation of the LEU2
and lacZreporter genes. In contrast, Caspase-10 was activatedwhen
FADD was expressed in these engineered yeast cells (Figure S13).
Screening 2.2610
6 clones from aHEK293cell libraryresulted in55
positives, of which 24 encoded FADD (Figures S14, S15). These and
other cDNA library screening experiments demonstrated the robust
performance of the cleavable reporter-based screening system for
studying proteases, illustrated here for the DISC (Fas/FADD/
Caspase-8/10).
Adaptation of the yeast-based Caspase activation assay
to HTS
We have implemented the yeast-based protease reporter system
in HTS compatible formats by revising conditions from agar plates
to liquid medium in microtiter wells. To this end, we measured
b-galactosidase produced by yeast carrying the Caspase-cleavable
reporter proteins, assaying the colorimetric product (OD620 nm)
derived from X-gal substrate in 384 well plates, as a measure
of the lacZ reporter gene activity. Comparisons were made of
b-galactosidase activity produced in the presence or absence of
the broad-spectrum Caspase inhibitory compound, zVAD-fmk
(benzoyl-Valinyl-Alaninyl-Aspartyl-fluoromethylketone). Among the
variables that were initially interrogated were initial seeding cell
density, time of culture, concentration of X-gal substrate, and
supporting carbohydrate (raffinose vs mannose) (Figures S16 and S17).
Note that we cannot employ glucose in yeast media because it
represses the GAL1 promoter used in some plasmids. All variables
tested alter the signal to noise ratio of the assay. For the Fas/FADD/
Caspase-8 multi-component assay, the best results were achieve with
,2610
5 cells per well starting density cultured for ,3d a y si n
raffinose-containing media with 400 ug/mL concentration of X-gal
substrate. For the 2-component system of Asc/Caspase-1, the same
conditions were optimal, among those tested (not shown). For the
NLRP1DLRR/Asc/Caspase-1 multi-component assay, the best
results were achieved with ,2610
5 cells per well starting density
cultured for ,3 days in raffinose-containing media with 400 mg/mL
concentration of X-gal substrate.
We further validated the 384 well assay format, using zVAD-
fmk, a peptidyl inhibitor with broad-spectrum activity against
animal Caspases. For some experiments, a Calpain inhibitor was
employed in side-by-side experiments as a control. The broad-
spectrum Caspase inhibitor zVAD-fmk inhibited b-galactosidase
activity in a dose-dependent fashion, with the concentration
required for achieving 50% inhibition ranging from ,1–10 mMi n
these assays, which were performed in 384 well format (Figure 5)
(Table S1). In contrast, the Calpain inhibitor did not suppress
activation of the lacZ reporter gene. These experiments verify that
the 384 well version of the yeast-based Caspase-dependent
reporter gene assay faithfully indicates the activity of an inhibitory
Figure 5. Validation of yeast-based assay using pharmacological inhibitor of Caspases. (A) Caspase-1, single component assay. EGY48
yeast cells expressing S1 substrate (TEF-Fas-d-S1-TA) and high levels of Caspase-1 (TEF-HA-Caspase1-FLAG) were incubated for 3 days in selection
media (SD/X-gal) with the indicated concentrations of z-VAD-fmk in DMSO (N) or DMSO only (#), using 384-well plates. (B) Asc/Caspase-1 two-
component system. EGY48 yeast cells expressing S1 substrate (TEF-Fas-d-S1-TA) a low level of pro-Caspase-1 (DTEF1-Caspase1-FLAG) and high levels
of Asc (TEF-HA-Asc) were incubated for 3 days in the selection media (SD/X-gal) in 384 well plates with the indicated concentrations of calpeptin (m)
or z-VAD-fmk (N) or an equivalent volume of DMSO (#). (C) Fas/FADD/Caspase8 three-component system. EGY48 yeast cells expressing S8 substrate
(TEF-S8-TA), low levels of pro-Caspase-8 CYC1-Caspase-8-HA, with a small amount of FADD (from DADH1 promoter) and a large amount of Fas (from
ADH promoter), were incubated in selection media (SD/X-gal) with the indicated concentrations of calpeptin (m) or z-VAD-fmk (N), or equivalent
volume of DMSO (#), in 384-well plates for 3–4 days. For (A–C), relative absorbance at 620 nm was measured (mean 6 std dev; n=325 independent
experiments). (* indicates p,0.001).
doi:10.1371/journal.pone.0007655.g005
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HTS assays.
To assess the reproducibility of the 384 well microplate assay,
we prepared multiple replicate wells in 384 well plates representing
the negative (assay max) and positive (assay min) controls for the
assays. For the 3-component systems of Fas/FADD/Caspase-8
and NLRP1DLRR/Asc/Caspase-1, the maximum signal was
produced by cells grown with X-gal substrate, while the minimum
was set by either cells grown without X-gal substrate (Figure 6) or
by adding ZVAD-fmk (Figure S18). For both assays, Fas/FADD-
mediated activation of Caspase-8 and NLRP1DLRR/Asc-medi-
ated activation of Caspase-1 resulted in activation of the cleavable
transcription factor, producing b-galactosidase, which was mea-
sured using a colorimetric substrate. We empirically adjusted the
yeast cell density, incubation time, and other variables to format a
384 well assay. The Z’ factors for the Fas/FADD/Caspase-8 assay
and the NLRP1DLRR/Asc/Caspase-1 assay were determined by
reading multiple replicates of the assay max and min, and
determined be .0.6 and .0.6, respectively, and thus suitable for
HTS (Figure 6A, 6C and S18).
We then performed automated pilot screens of 1280 com-
pounds (LOPAC library) using the Fas/FADD/Caspase-8 and
NLRP1DLRR/Asc/Caspase-1 assay, achieving an average hit rate
of ,0.5 and ,0.5 per 384 well plate, respectively, which is quite
acceptable particularly given that the library is enriched in bioactive
molecules. Examples of primary screening results are shown
(Figures 6B, D). We further evaluated the 8 hits obtained using
the Fas/FADD/Caspase-8 screen using a combination of engi-
neered yeast cells carrying vectors designed for post-HTS
compound profiling and using in vitro enzymatic assays for
b-galactosidase and Caspase-8. The yeast cell lines employed for
deconvoluting hits included yeast constitutively expressing lacZ gene
to eliminate false-positives due to b-galactosidase inhibition and
Asc/Caspase-1 expressing yeast to eliminate hits that interfere with
a different Caspase or its upstream activator, in addition to original
Fas/FADD/Caspase-8-expressing yeast. Of 8 hit compounds, 4
inhibited b-galactosidase activity in yeast and in vitro, representing
false-positives. Two of the compounds showed selectivity for Fas/
FADD/Caspase-8 over Asc/Caspase-1, though displaying some
inhibition of the latter in the yeast-based reporter gene assay at
higher concentrations (Figures 6E, F). One of the compounds was
confirmed to be a direct inhibitor of Caspase-8 using a biochemical
assay with fluorigenic peptide substrate, showing concentration-
dependent inhibition of this protease with IC50 of ,2.6 mM
(Figure 6G). Thus, these yeast-based HTS assays are suitable for
compound library screening.
Application of yeast-based assay system for Autophagins
To explore the general utility of the yeast-based system for
assaying mammalian proteases, we turned to another class of
intracellular cysteine proteases, Autophagins. These proteases are
required for autophagy, with the human genome containing genes
encoding four family members – ATG4A, ATG4B, ATG4C, and
ATG4D [7]. The substrate specificity of Autophagins has been
partially determined, with glycine required at the point of
hydrolytic cleavage [29]. A physiological substrate of mammalian
Autophagins is the protein LC3. We therefore prepared a
cleavable, transmembrane fusion protein containing the LC3
protein fused between the membrane tethering Fas (CD95) protein
fragment described above and the chimeric LexA/B42 transcrip-
tion factor. The Autophagin family member ATG4B or a mutant
in which the catalytic cysteine was converted to alanine (C/A) was
expressed from a TEF inducible plasmid in yeast with the
engineered LC3 substrate (Figure 7A). Culturing the transformed
cells on X-gal plates showed that the LexA-reponsive lacZ reporter
gene was activated upon expression of ATG4B but not the
ATG4B(C/A) mutant (Figure 7B). Substituting Caspase-1 for
ATG4B also failed to activate the reporter gene (not shown). To
explore the utility of the Autophagin assay for HTS, we adapted it
to the 384 well format by optimizing cell density and incubation
time (Figure S19). Multiple replicate wells were prepared with
EGY48 strain yeast expressing plasmids encoding ATG4B
(maximum signal) or ATG4B(C/A) mutant (minimum signal),
showing robust assay performance (Z’ factor.0.7) (Figure 7C).
Thus, the technology described here can be adapted to additional
classes of intracellular protease, as evidenced by these experiments
using ATG4B.
Discussion
Proteases play important roles in a wide variety of cellular
processes and diseases. Proteases can be found in either
intracellular or extracellular (or cell surface) locations, where they
encounter their specific substrates. Among the intracellular
families of proteases are Caspases, Autophagins, Calpains,
Deubiquitinating enzymes (DUBs), Presenilins, and Separases.
Still other proteases may have dual intracellular and extracellular
lives. For example, Cathepsins are normally stored in lysosomes
undergoing vesicular recycling between extracellular and intracel-
lular compartments, but also are released into the cytosol under
various pathological circumstances [30]. Moreover, many clini-
cally significant viruses encode proteases that are candidate targets
for drug discovery.
From the standpoint of high-throughput screening (HTS) for
identifying chemical inhibitors of proteases, many endopeptidases
(or at least their catalytic domains) can be readily produced in
large quantities by recombinant DNA technology, purified, and
formatted for HTS using convenient fluorigenic or colorimetric
substrates. However, such assay formats have several limitations.
First, standard HTS configurations for proteases are typically
amenable only to screens for inhibitors, not activators of proteases.
Second, assays requiring large amounts of purified, active protease
can be hampered by difficulties in producing by recombinant
methods or purifying from endogenous sources sufficient amounts
of material, as well as by instability problems where purified
proteases lose activity in vitro. Third, because one is often limited
to using only the catalytic domain due to difficulties of expressing
and purifying intact full-length proteases, opportunities to discover
allosteric modulators of proteases are limited, with most of the
standard assays favoring identification of compounds that target
the active site in a competitive fashion. Fourth, when using single
target systems consisting of purified protease or catalytic domain of
protease, opportunities for identification of compounds that target
other proteins involved in protease activation are lost. Fifth,
several classes of intracellular endopeptidases exists as large
families of closely related enzymes with structurally very similar
active sites, making it difficult to achieve selective inhibitors in the
absence of more context-dependent, multi-component systems
that would provide the opportunity for selective inhibition. Sixth,
some proteases are not active in purified form, requiring necessary
cofactors (e.g. Separins involved in chromosome segregation and
cell division) or requiring membranes (e.g. Presenilins [c-secretase]
involved in Amyloid-beta-peptide processing).
For these and other reasons, it would be desirable to have cell-
based alternatives to in vitro biochemical assays for protease HTS.
Our goal was to develop adaptable approaches for reconstituting
in yeast protease activation pathways and networks, using
Caspases as a prototype. The HTS implementation of complex
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Yeast cells (18 ml, typically at <2610
5 cells/well) containing NLRP1DLRR/Asc/Caspase-1 were plated into wells of 384 well plates in media containing
1% galactose, 0.2% raffinose. Wells also contained 18 mL selection media with (blue squares) or without (purple diamonds) X-gal substrate (400 mg/
mL final Concentration) plus 10% DMSO (4 ml) (to simulate compound addition). The plates were incubated for 72 hrs at 30uC and the OD620 was
recorded. Values (mean6std dev) were calculated for the assay maximum and minimum. The Z’ factor was calculated as described [45]. (B) Example
of library screening plate for NLRP1-Asc-Caspase-1. Yeast cells (typically at <2610
5 cells/well) containing NLRP1/Asc/Caspase-1 were plated in 384 well
plates in Selection Media, without (purple triangles) or with (all other wells) 400 mg/ml X-gal (final concentration). Compounds in DMSO (,10 mM
final) had been pre-added to wells (diamonds). The plates were incubated for 72 hrs at 30uC and the OD620 was recorded, ‘‘Hits’’ were defined by
.50% reduction (as shown in green diamonds). (C) Validation of HTS assay for Fas-FADD-Caspase-8 system. Yeast cells containing Fas/FADD/Caspase-
8 were cultured in 384 well plates as above with (blue squares) or without (purple diamonds) X-gal substrate, the plates were incubated for 72 hrs at
30uC and analyzed as above. (D) Example of library screening plate for Fas-FADD-Caspase-8. Yeast cells containing Fas/FADD/Caspase-8 were plated at
<2610
5 cells/wells in 384 well plates in Selection Media, without (purple triangles) or with (all others) 400 mg/ml X-gal (final concentration), and
without (triangles, squares) or with (diamonds) compounds in 10% DMSO (,10 mM final). Plates were incubated for 48 hrs at 30uC and OD620 values
recorded. ‘‘Hits’’ were defined by .50% reduction (shown as green diamonds). (E,F) Examples of compounds showing evidence of selective inhibition of
Fas-FADD-Caspase-8. EGY48 yeast cell lines employed for deconvoluting hits included yeast expressing lacZ gene (.) expresses LexA/B42
transcription factor from GAL1 promoter; cells grown in galactose media to induce promoter) to eliminate false-positives due to b-galactosidase
inhibition and Asc/Caspase-1-expressing yeast (&) to eliminate hits that interfere with a different Caspase. Yeast containing empty vector were also
included (X). Yeast cells (at 2610
5 cells/well) containing Fas/FADD/Caspase-8 (m) or other strains were cultured in 384 well plates in a total volume of
40 mL Selection Media, with 400 mg/ml X-gal final concentration, without (‘‘C’’) or with various concentrations of compound CID-5154 or CID-3101.
The plates were incubated for 2–4 days at 30uC and OD620 values recorded. (G) Example of compound showing evidence of inhibition of Caspase-8.A n
in vitro biochemical assay was used containing purified recombinant Caspase-8 and fluorigenic substrate Ac-IETD-AFC. Data represent relative
fluorescence units (RFU) assessed in the absence or presence of various concentrations of compound (CID-2531).
doi:10.1371/journal.pone.0007655.g006
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robust performance of the configured assays, in which we carefully
titrated levels of various components by (a) using promoters of
different strengths, (b) employing low versus high copy yeast
plasmids; and (c) utilizing reporter genes with different numbers of
transcription factor binding sites in their promoters. Acceptable Z’
Figure 7. Yeast-based HTS assay for ATG4B. (A) The basis for the yeast-based cleavable reporter assay for monitoring ATG4B activity is
depicted. The membrane tethered transcription factor (TF) consists of the DNA-binding domain of the LexA protein and the transactivation domain
of the B42 protein, fused to LC3 and the extracellular and transmembrane domains of Fas. ATG4B cleaves LC3 to release the chimeric LexA/B42
transcription factor, leaving the membrane and entering the nucleus, where it induces expression of LEU2 and LacZ genes. (B) EGY48 yeast
transformed with plasmids encoding various proteases (ATG4B, ATG4B(C/A), Caspase-1) and various Fas-LexA/B42 substrates containing either LC3
protein or the WEHD tetrapeptide were streaked on standard media plates without (top) or with (bottom) Xgal substrate. Note that wild-type ATG4B
but not mutant ATG4B(C/A) activated the lacZ reporter gene. (C) For HTS implementation, multiple replicate wells were prepared of yeast cells
(100 mL/well at 10
4 cells/mL) expressing LC3-containing substrate and either ATG4B (red) or ATG4B(C/A) mutant (blue) in 384 well plates using media
containing 1% galactose/2%raffinose, with X-gal substrate. Cells were cultured for 48 hrs at 30uC before recording OD 620 nm values.
doi:10.1371/journal.pone.0007655.g007
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concept screens of a small library enriched in bioactive compounds
demonstrated acceptable hit rates. Post-HTS deconvolution of hit
compounds is readily achieved by using yeast engineered with
progressively reduced complexity (reporter gene only, protease
only, etc.) to reduce or eliminate false-positive compounds that
directly inhibit the reporter gene or its product (b-galactosidase)
and to differentiate compounds that inhibit the protease versus
upstream activators of the protease. Selectivity of compounds is
also readily interrogated by using various Caspase assays described
here as counter-screens. In this regard, we succeeded to
reconstitute in yeast all ten human Caspases with cleavable
transcription factor reporters, thus covering the entire family of
these proteases. We also demonstrated the versatility of the
technology by configuring an assay for autophagins.
Mammalian and invertebrate Caspases have been expressed in
yeast previously for basic research purposes but configuration of
yeast-based Caspase assays suitable for HTS have not been
described heretofore. A cleavable membrane-tethered transcrip-
tion factor was previously described by Hawkins and Hay, and
used to define the substrate specificity of an invertebrate Caspase
(Ced3) and to explore the activities of endogenous inhibitors of
Caspases (IAP family proteins) [8,9]. Similarly, a cDNA library
cloned into a membrane tethered transcription factor was used
for functional cloning of Caspase substrates in yeast [31]. By
exploiting the ability of over-expressed Caspases to kill yeast, and
thus using cell death as an endpoint (rather than a reporter gene
strategy), reconstitution of Caspase activation pathways has been
previously achieved in yeast for the 3 component network of
Apaf1/Caspase-9/Caspase-3 [32,33] and the 2 component
networks of Ced4/Ced3 [34,35], Caspase-2/Caspase-7 [11],
Caspase-8/Caspase-3, and Caspase-10/Caspase-3 – in some cases
together with animal or viral protein inhibitors of these proteases
[12,13,19]. In another application, yeast cells have been modified
to express a viral protease (TEVP) together with an engineered
substrate that releases an endonuclease (DFF4) to kill yeast [36].
Also, a 4-component system has been reconstituted in yeast for c-
secretase activity, comprised of Presenlin-1, Nicastrin, APH-1, and
PEN-2, using lacZ (b-galactosidase) reporter gene activation by a
membrane-tethered cleavable transcription factor (Amyloid b-
protein precursor [APP] fused to GAL1 transcription factor) as an
endpoint for assessing activity of this transmembrane protease
complex [37]. The suitability for HTS of these other systems in
which heterologous proteases were reconstituted in yeast has not
been demonstrated. A mammalian cell assay based on endogenous
secretase-mediated cleavage of an APP-Gal4-VP16 fusion protein
that activates a luciferase reporters gene has been implemented as
a HTS screen [38], but has the limitation that more than one
endogenous mammalian protease can cleave this engineered
substrate.
The yeast-based assays for proteases described here were also
successfully exploited for functional cDNA library screening, in
addition to compound library screening. By using two sequential
selections based on LEU2 (growth on leucine-deficient media) and
lacZ (blue color on X-gal plates) reporter gene activity, false-
positive clones were reduced, resulting in a high proportion of
cDNAs that were clearly true-positives (124 of 276 total cDNA hits
tested from 11 separate cDNA library screening experiments).
Moreover, some of the cDNA hits that we called false-positive may
with further investigation prove to actually be genuine regulators
of the Caspases activation pathways used for screening. With the
exception of screen for substrates of proteases [31], we are
unaware of prior reports that successfully used cleavable
transcription factor/reporter gene read-outs for functional cDNA
library screening in yeast or other types of eukaryotic cells for
Caspases or other types of intracellular proteases. Cell death has
been successfully employed as an end-point for screening a cDNA
library in search of protein inhibitors of Caspases, where cDNA
clones that rescued yeast from a Caspase-mediated lethality were
identified [8]. Reporter gene-based screens and lethality-based
screens presumably each introduce different types of bias, and
could even be used in tandem to efficiently reduce false-positives in
functional cDNA library screening projects. Similarly, reporter
gene-based and lethality-based screens of Caspases in yeast could
be applied in tandem for compound library screening, using
various colorimetric and fluorigenic indicators of yeast cell viability
for the latter in microtiter plate format. However, not all Caspases
[18] and not all animal or viral proteases ectopically expressed in
yeast produce lethality or growth inhibitory phenotypes, thus
precluding the use of viability/growth rescue as a general strategy
for functional cDNA library screening or compound library
screening.
In summary, we described versatile expression vectors that
provide a range of levels of expression of heterologous proteins in
yeast, plasmids encoding a transcription factor substrate with a
cleavable linker to accommodate various protease specificities, and
methods for configuring complex multi-component protease activa-
tion pathways for high throughput chemical library screening. These
uniqueassaycomponentsandmethodsweredemonstratedforallten
human Caspases and for a human autophagin (ATG4B). The
described technology platform thus provides powerful tools for
identification of compounds or cDNAs that modulate the activity of
these and other classes of intracellular proteases and their cellular
regulators.
Methods
Additional methodological details are provided as supplemental
information (Supplemental Methods S1).
Plasmid Constructions
Vectors encoding Caspase or Autophagin cleavable
transcription factors. The reporter, Fas-d-S1-TA for Caspase-
1 and related proteases (called ‘‘S1’’), was generated by using PCR
and standard recombinant DNA techniques modeled after a
previous report [8]. This protein consists of, from N to C termini,
amino acidsM
1-L
224 ofa type1 transmembrane protein, human Fas
[39] in which Fas is devoid of the cytosolic death domain (Fas-d), a
linker containing the sequence GWEHDG between a XhoI and
EagI site, and finally a transcriptional activator (TA) containing the
LexA DNA binding domain and the B42 activation domain, taken
from plasmids pRS305(Dwbp1-Cub-PLV) [40] and pJG4-5
(Invitrogen) with PCR. Other reporters were made by substituting
the linker with oligonucleotides designed to encode in-frame the
sequences GWEHGG (‘‘G1’’), GDEHDG (‘‘S2’’), GDEHGG
(‘‘G2’’), GDEVDG (‘‘S3’’), GDEVGG (‘‘G3’’), GTEVDG (‘‘S6’’),
GTEVGG(‘‘G6’’),GLETDG(‘‘S8’’),GLETGG(‘‘G8’’),GLEHDG
(‘‘S9’’), GLEHGG (‘‘G9’’), or PCR-amplified LC3B gene, after
digestion with XhoI and EagI.
Plasmids for expressing Caspases and their upstream
activators. Plasmids for expression of Caspases in yeast were
derived from pRS series vectors [41,42,43] and pESC series
vectors (Stratagene [Agilent]). Expression levels were adjusted by
using constitutive promoters of different strengths (CYC1, ADH,
TEF, and GPD) [44] or using the inducible GAL1 promoter, in
conjunction with different strength reporter genes carrying
variable numbers of lexA operators [10], and using plasmids with
different replication origins for low or high copy number
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levels, we made several attenuated forms of the promoters by PCR-
assisted deletional mutagenesis. Using a standard indicator gene, we
determined the approximate relative strength of the promoters to
be: DCYC4 , DCYC2 , CYC1 , DGPD2 , DGPD1 , DADH1
, ADH , DTEF3 , DTEF2 , DTEF1 , TEF. However, the
relative locations of the promoters in complex plasmids somewhat
affects their strength, especially when two or three genes are
contained in one plasmid. In this regard, we sometimes co-
expressed two or three genes within one plasmid by placing the
genes flanked by the above promoters and inserting transcription
termination elements between them, because the selectable marker
genes available are limited (URA3, HIS3, TRP1, and LEU2). In
addition, many of the expressed Caspases and upstream activators
were cloned with N-terminal HA or C-terminal HA or FLAG
epitope tags for convenience of detection of the protein products by
immunoblotting. Examples of complex plasmids are (a) p413-TEF-
Fas-d-S8-TA/CYC1-Caspase8-HA, which consists of CEN/ARS
origin, HIS3 marker, Fas-d-S8-TA substrate driven by TEF
promoter, and a C-terminally HA-tagged pro-Caspase-8 cDNA
under control of the CYC1 promoter, as in Figure S20C, and (b)
p426-2op-lacZ/DADH1-FADD, which consists of 2m origin, URA3
marker, lacZ gene under the control of two lexA operators, and a
FADD gene with expression driven by a short form of the ADH
promoter (DADH1), as in Figure S21C. Further details about
plasmid constructions are provided as Supplemental Information.
Construction of expression cDNA libraries. Oligo(dT)-
primed or random heptamer-primed cDNA libraries were made in
modified p424-GAL1, p424-GAL1-HA, p424-ADH, or p424-
ADH-HA plasmids (carrying a TRP1 marker) using mRNAs
derived from HEK 293 cells, HepG2 cells, HeLa cells, human
liver, or human placenta, as in Supplemental Figure S22A. The
mRNAs of HepG2 cells, HeLa cells, human liver, and human
placenta were purchased from Ambion. The p424-GAL1 was
modified to create 59XhoI and 39NotI sites downstream of a
GAL1 promoter for insertion of the cDNAs. The p424-GAL1-HA
has a HA-tag between the GAL1 promoter and the 59XhoI site.
The p424-ADH and p424-ADH-HA plasmids were modified with
59XhoI and 39SfiI sites downstream of the ADH promoter. To
construct directional libraries, the first-strand cDNA syntheses
were initiated with a NotI-oligo(dT) primer adaptor or a NotI-
random hexamer primer adaptor for the p424-GAL1 and p424-
GAL1-HA, and with a SfiI-oligo(dT) primer adaptor or a SfiI-
random hexamer primer adaptor for the p424-ADH and p424-
ADH-HA, according to the manufacturer’s instructions
(Invitrogen). SalI adapters were ligated to the resultant double-
strand cDNAs prior to digestion with NotI or SfiI. The cDNAs
with SalI-NotI termini or with SalI-SfiI termini were ligated into
the plasmid cloning vectors (XhoI-NotI-cut or XhoI-SfiI-cut,
respectively). The number of initial transformants ranged from
1.3610
6 to 1.3610
7. A human B cell cDNA library was purchased
from ATCC. The oligo(dT)-primed cDNAs were inserted into the
XhoI cloning site, downstream of a GAL1 promoter. Procedures
used for cDNA library screening are provided as Supplemental
Information.
Reporter gene assays. Plasmids were introduced into yeast
by lithium acetate transformation. The yeast strain EGY48, which
carries 6 lexA operators upstream of LEU2 gene (6op-LEU2), was
transformed with pJK103 [10], which carries two lexA operators
upstream of lacZ gene (p426-2op-lacZ), and subsequently with
reporter plasmids (p413-TEF-Fas-d-S1-TA, p413-TEF-Fas-d-G1-
TA, p413-TEF-Fas-d-S2-TA, p413-TEF-Fas-d-S3-TA, p413-TEF-
Fas-d-S6-TA, p413-TEF-Fas-d-S8-TA, or p413-TEF-Fas-d-S9-
TA). Caspase (all full-length zymogen proforms) expression
plasmids (p424-ADH-Caspase1-FLAG, p424-ADH-HA-Caspase2,
p424-ADH-Caspase3, p424-TEF-Caspase4, p424-ADH-Caspase5,
p424-TEF-HA-Caspase6, p424-ADH-Caspase7, and p424-ADH-
HA-Caspase9-FLAG) or empty vector (p424-ADH), were intro-
duced into thesebackgrounds.Asforassayswith Caspase-8and -10,
we expressed small amounts of pro-Caspase-8 and -10 with a large
amountofFADD bytransformingyeastwith the dual gene plasmids
p424-CYC1-Caspase8-HA/TEF-HA-FADD and p424-CYC1-
Caspase10-FLAG/TEF-HA-FADD, because expression of large
amounts of human Caspase-8 or Caspase-10 significantly inhibited
the cell growth. For ATG4 assays, the yeast strain EGY48 was
transformed with ATG4B or catalytic mutant ATG4B(C/A)
plasmids (p424-TEF-ATG4B-FLAG or p424-TEF-ATG4B(C/A)-
FLAG), reporter plasmid (p413-TEF-Fas-d-LC3B-TA), and
pJK103 or pSH18-34 [10], which carries eight lexA operators
upstream of a lacZ gene. The transformants (two independent
colonies for each transformation) were streaked on growth plates
(minimum synthetic dropout (SD) medium containing 2% glucose
and 50 mg/ml leucine) or on selection plates (SD medium
containing 1% galactose, 0.2% raffinose, BU salts, and 80 mg/ml
X-gal). Yeast growth and blue color development were monitored
for four to six days at 30uC.
Reporter gene assays in liquid media using 384-well
plates. For caspase assays, the assays were performed in a total
volume of 40 ml in triplicate. First, 20 ml of liquid selection media
containing X-gal and a series of concentrations of reagents such as
z-VAD was dispensed into each well of 384-well plates. Next,
confluent yeast cells expressing various Caspases and cleavable
substrates were collected, washed with water, and suspended in
selection media of the same volume as the culture media. The
yeast suspension was diluted to 1:5-10 (v:v) with the selection
media, and 20 ml aliquots were added to the 384-well plates. For
ATG4B assays, yeast cells expressing ATG4B and LC3 fused-
transcription factor were cultured overnight in standard growth
medium, then the yeast cells were diluted in selection medium (SD
medium containing 1% galactose, 0.2% raffinose, BU salts, and
100 mg/ml X-gal) at 10
4/ml and dispensed 100 ml into each well
of 384-well plates. Absorbance at 620 nm was measured 2–3 days
after culture at 30uC.
HTS Assays. For the Fas/FADD/Caspase-8 and the NLRP1/
Asc/Caspase-1 assays, EGY48 yeast containing the desired plasmids
were streaked onto SD plates (6.8 g Yeast Nitrogen Base w/o amino
acids, 20 mg arginine, 50 mg threonine, 30 mg isoleucine, 60 mg
phenylalanine, 20 mg valine) containing agar (1.7%), supplemented
with 2% a-D-glucose and 50 mg/mL leucine. The plates were
incubated at 30uC for 48 hrs and a colony was picked and
transferred to a 14 ml polypropylene tube containing 2 ml of SD
media broth supplemented with a-D-glucose and leucine as above
and grown at 30uC for 16–24 hrs with shaking. Then, 1 ml of the
overnight culture was transferred into 20 mls of growth media in a
500 ml flask and shaken at 30uC for 16–24 hrs. The cells were
collected by centrifugation at 1000xg for 5 minutes at room
temperature, and washed with 20 mls of sterile water, then
resuspended in 20 mls of SD broth supplemented with 1%
galactose and 0.2% raffinose. The HTS Assay was performed at a
final compound concentration of 10 mM (1% DMSO), with cell
densities of 2610
5 cells/ml (2610
5 cells) in a volume of 40 ml. The
assaywasassembled bytheadditionof4 mlo f<100 mMcompounds
(final concentration of 10 mM) in 10% DMSO (1% final DMSO) to
clear polystyrene 384-well microplates using a Beckman-Coulter
Biomek FX, then 18 ml of cell suspension (1.1610
7 cells/ml)
(2610
5 cells/well) and 18 ml of X-gal suspended in Selection
Media (for a final concentration of 400 mg/mL) were added to the
wells using a Matrix WellMate bulk reagents dispenser. Remaining
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Technologies Corp. Controls were included with each plate,
corresponding to cells treated with DMSO (without compounds)
and cells cultured with and without X-gal. The plates were sealed
with breathable sealing film (from Axygen Scientific) to reduce
evaporation and transferred to 30uC incubators. After 48 hours, the
plates were brought to room temperature, the breathable film
removed and replaced with the transparent polyester tape seal, and
the plates were mixed, pelleted briefly and read using a Beckman
DTX 880, recording absorbance at 620 nm.
Yeast-based counter-screen assays. EGY48 yeast inducibly
(GAL1 promoter) expressing the LexA/B42 transcription factor or
containing the empty vector were used to detect compounds that
directly inhibit the lacZ reporter gene or that alter b-galactosidase
activity.The plasmidsemployed were p424-GAL1 andp424-GAL1-
TA (transcriptional activator) with transformed cells selected on
tryptophan-deficient plates. Yeast expressing Caspase-1 activated by
expression of high levels of Asc (DTEF3-Caspase-1-FLAG/TEF-
HA-Asc) were used to detect compounds that cross-react with hits
from the Fas/FADD/Caspase-8 screen. The Asc/Caspase-1 yeast
cells were cultured and assayed under identical conditions to those
forthe primaryNLRP1HTS assay(seeabove),usingcellsexpressing
6op-LEU2/2op-lacZ reporter genes and TEF-Fas-d-S1-TA
substrate.
Supporting Information
Supplemental Methods S1
Found at: doi:10.1371/journal.pone.0007655.s001 (0.03 MB
PDF)
Table S1 Determination of IC50 values for zVAD-fmk
inhibition of Caspases in yeast. Yeast expressing various Caspases
alone (at high levels) or in combination with upstream activators
(at low levels) and cleavable substrates containing appropriate
tetrapeptides reorganized by these proteases were used in 384 well
b-galactosidase activity assays to assess inhibition by zVAD-fmk.
The compound was titrated into assays at various concentrations
and percentage inhibition was determined. IC50 values were
determined, using PRIZM software for analysis.
Found at: doi:10.1371/journal.pone.0007655.s002 (0.01 MB
PDF)
Figure S1 Substrate sequence- and Caspase activity-dependent
cleavage of the S1, S2, and S9. Yeast transformants were plated on
leucine-deficient medium containing X-gal. (A) The recipient yeast
cell strains, EGY48-6op-LEU2/2op-lacZ/TEF-Fas-d-S1(WEHD)-
TA (S1), or EGY48-6op-LEU2/2op-lacZ/TEF-Fas-d-G1(WEHG)-
TA (G1) were transformed with the plasmids encoding the active
wild type Caspase1 (WT), the catalytically-defective Caspase1
(C285RG285), and the empty vector (-). (B) The recipient yeast cell
strains, EGY48-6op-LEU2/2op-lacZ/TEF-Fas-d-S2(DEHD)-TA
(S2), or EGY48-6op-LEU2/2op-lacZ/TEF-Fas-d-G2(DEHG)-TA
(G2) were transformed with the plasmids encoding the active
wild type Caspase2 (WT), the catalytically-defective Caspase2
(C320RA320), and the empty vector (-). (C) The recipient yeast cell
strain, EGY48-6op-LEU2/2op-lacZ/TEF-Fas-d-S9(LEHD)-TA
(S9), or EGY48-6op-LEU2/2op-lacZ/TEF-Fas-d-G9(LEHG)-TA
(G9), were transformed with the plasmids encoding the active
wild type Caspase9 (WT), the catalytically-defective Caspase9
(C287RA287), and the empty vector (-).
Found at: doi:10.1371/journal.pone.0007655.s003 (0.05 MB
PDF)
Figure S2 Flow chart for cDNA library screening using a
reporter gene strategy based on cleavable transcription factor. The
example here is S1 substrate. The yeast strain EGY48 containing
6op-LEU2 and 2op-lacZ reporter genes and Caspase-cleavable
substrate (expressed from TEF-Fas-d-S1-TA) was transformed
(left) with a HEK293 cell cDNA library (oligo-dT-primed, PGAL1
promoter). Independent colonies of 5.16105 clones appeared on
growth plates in 48 hours. Cells were collected, pooled, and a
portion (3.66106) was seeded on leucine-deficient selection plates
containing X-gal. Blue-colored colonies (n=42) appeared within a
week, of which 6 corresponded to clone #ZB311 encoding full-
length Caspase-4 (which is known to cleave WEHD tetrapeptide
[Thornberry, N.A, et. al., J. Biol. Chem. 272, 17907–17911
(1997)]), while the rest were false positives. (Right) Another cDNA
library screen (HEK293 random-primed, ADH promoter used to
drive expression) resulted in 26106 clones, which were pooled and
2.16107 cells were screened on leucine-deficient, X-gal-containing
plates, resulting in 10 blue colonies. Five clones (including
#XE501) encoding a fragment of Casapse-1 (L89-G403) were
isolated. The remaining five clones were apparent false positives.
Found at: doi:10.1371/journal.pone.0007655.s004 (0.04 MB
PDF)
Figure S3 Flow chart for cDNA library screening using reporter
gene strategy based on cleavable transcription factor. The example
here is S3/S7 substrate. Yeast strain EGY48 containing 6op-
LEU2 and 2op-lacZ reporter genes and the DEVD-containing
cleavable transcription factor (expressed from TEF-Fas-d-S3-TA)
was transformed with a HEK293 cell cDNA library (random-
primed, PGAL1 promoter, HA-tagged) (left). Independent colo-
nies (1.06106) appeared on growth plates within 48 hours. Cells
were collected, pooled, and a portion (5.06106) was seeded on the
leucine-deficient selection plates containing X-gal. Blue-colored
colonies (n=21) appeared within a week, of which 3 clones
(including #ZB331) encoded full-length Caspase-3, while the rest
were false positives. In a similar experiment (right), another
HEK293 cDNA library (oligo-dT-primed, PADH promoter)
(1.86106 initial colonies) was screened, resulting in 9 positive
clones (including #X8312) encoding full-length Caspase-7. The
remaining five clones were false positives. Both cloned Caspases
are known to cleave DEVD tetrapeptide [Thornberry, N.A, et. al.,
J. Biol. Chem. 272, 17907–17911 (1997)].
Found at: doi:10.1371/journal.pone.0007655.s005 (0.04 MB
PDF)
Figure S4 Use of one-component yeast-based Caspase activity
assay for cDNA library screening. (A) The plasmids containing
library cDNAs from Figure S2 were recovered and re-transformed
into yeast cells containing 6op-LEU2 and 2op-lacZ reporter genes
with either cleavable (WEHD-containing) (expressed from TEF-
Fas-d-S1-TA) or non-cleavable (WEHG-containing) transcription
factor substrate (expressed from TEF-Fas-d-G1-TA) to confirm
whether they cleave S1 specifically. As controls, yeast were
transformed with a plasmid encoding Caspase-1 (‘‘Positive’’
control) or the empty vector (‘‘Negative’’ control). Assays were
performed in duplicate, with cells grown on selection plates for 4
days. Note that the cDNA library clones supported lacZ reporter
gene activation only when co-expressed with the S1 cleavable
substrate. (B) The cDNA library plasmids from Figure S3 were
recovered and used to re-transform the yeast strains containing
either the same cleavable DEVD-containing or DEVG non-
cleavable transcription factor, expressed from TEF-Fas-d-S3-TA
(‘‘S3’’ substrate) and TEF-Fas-d-G3-TA (‘‘G3’’ substrate), respec-
tively. Assays were performed in duplicate and cells grown on
selection plates for 4 days. Note that the two cDNA library clones
activated the lacZ reporter gene only when co-expressed with
cleavable S3 (DEVD-containing) substrate. As controls, yeast cells
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control) or the empty vector (‘‘Negative’’ control).
Found at: doi:10.1371/journal.pone.0007655.s006 (0.04 MB
PDF)
Figure S5 Validation of yeast-based assays for effector Caspase
activators - two- and three-component systems. Yeast EGY191 strain
containing 2op-LEU2/2op-lacZ or EGY48 strain containing 6op-
LEU2/2op-lacZ were employed for developing assays for activators of
downstream effector Caspases (e.g. Caspases-3 and -7). Yeast
transformants were plated on leucine-deficient medium containing
X-gal. Yeast were transformed with plasmids encoding membrane
tethered transcription factor substrate with either DEVD-containing
cleavable (S3) or DEVG-containing non-cleavable (G3) linkers, and
with plasmids encoding pro-Caspase-3 (C3) or pro-Caspase-7 (C7) or
the corresponding empty vector (-). (Note that the optimal tetrapeptide
sequence for both Caspase-3 and Caspase-7 has previously been
reported to be DEVD). Yeast transformants were as follows: (A) S3
Substrate/No Caspase: EGY191-2op-LEU2/2op-lacZ/DTEF3-Fas-
d-S3 (DEVD)-TA; S3 Substrate/Caspase-3: EGY191-2op-LEU2/
2op-lacZ/DTEF3-Fas-d-S3/7(DEVD)-TA/DCYC2-HA-Caspase3;
G3 Substrate/Caspase-3: EGY191-2op-LEU2/2op-lacZ/DTEF3-
Fas-d-G3/7(DEVG)-TA/DCYC2-Caspase-3;and (B) S3Substrate/
No Caspase: EGY48-6op-LEU2/2op-lacZ/TEF-Fas-d-S3(DEVD)-
TA; S3 Substrate/Caspase-7: EGY48-6op-LEU2/2op-lacZ/TEF-
Fas-d-S3(DEVD)-TA/CYC1-Caspase-7; G3 Substrate/Caspase-7:
EGY48-6op-LEU2/2op-lacZ/TEF-Fas-d-G3(DEVG)-TA/CYC1-
Caspase-7. These yeast transformants were then subsequently
transformed with plasmids expressing a small amount of Caspase-9
(driven from the CYC promoter) or plasmids expressing large
amounts of wild-type (WT) or catalytically-defective (C287RA287)
Caspase-9 (driven from the TEF promoter), with or without an
active form (gain of function mutant not requiring cytochrome c for
activation) of Apaf-1 (driven by TEF-promoter) or the correspond-
ing empty vectors (-) (Haraguchi M, Torii S, Matsuzawa S, et al.
J Exp Med 2000;191:1709-20). Note that the large amount of
Caspase-9 (expressed from TEF promoter) activated the cleavable
S3(DEVD) substrate when co-expressed with pro-Caspase-3 or pro-
Caspase-7, but not in their absence, thus constituting a 2-
component system. No lacZ reporter gene activity was detected
when the non-cleavable substrate (DEVG) was employed (G3). In
contrast, expressing a small amount of Caspase-9 (from the CYC
promoter)or the catalytically-defective Caspase9 (C287RA287) did
not activate Caspase-3 or Caspase-7. However, co-expressing active
Apaf-1* with a small amount of pro-Caspase-9 activated the lacZ
reporter gene in yeast expressing pro-Caspase-3 or -7 (but not in the
absence of these downstream effector Caspases), thus constituting a
3-component system.
Found at: doi:10.1371/journal.pone.0007655.s007 (0.06 MB
PDF)
Figure S6 Validation of yeast-based assays for initiator Caspase
activators: two-component systems. Yeast EGY48 strain containing
6op-LEU2/2op-lacZ was employed for developing 2-component
assays for activators of upstream initiator Caspases (e.g. Caspases-1,
2, 8, 9, 10). Two independent clones of yeast transformants were
plated on leucine-deficient medium containing X-gal. Yeast were
transformed with plasmids encoding various membrane tethered
transcription factor substrates containing (A) WEHD (‘‘S1’’), (B)
DEHD (‘‘S2’’), (C) LEHD (‘‘S9’’) or (D) LETD (‘‘S8’’) cleavable
linkers or their corresponding non-cleavable glycine mutants (‘‘G1’’,
‘‘G2’’, ‘‘G9’’, ‘‘G8’’). The yeast were also transformed with plasmids
encoding wild-type (WT) or catalytically inactive mutants of
proforms various initiator Caspases expressed from relatively weak
promoters (e.g., CYC1; DTEF3), including (A) pro-Caspase-1, (B)
pro-Caspase-2, (C) pro-Caspase-9, and (D) pro-Caspase-10. (Note
that the optimal betrapeptide sequences are the same for Caspase-8
and 10). These yeast were transformed with empty vectors (-) or
plasmids encoding upstream activators of the Caspases, including (A)
Asc, (B) RAIDD, (C) Apaf-1*, and (D) FADD, expressed from strong
promoters (either GPD or TEF). Note that the lacZ reporter gene
was activated only when the combination of an initiator Caspase and
upstream activator was co-expressed, along with a cleavable
substrate. Transformants: The transformed yeast cell clones are: (A)
EGY48-6op-LEU2/2op-lacZ/TEF-Fas-d-S1(WEHD)-TA/DTEF3-
Caspase1-FLAG (S1,C1(WT)), EGY48-6op-LEU2/2op-lacZ/TEF-
Fas-d-G1(WEHG)-TA/DTEF3-Caspase1-FLAG (G1,C1(WT)), or
EGY48-6op-LEU2/2op-lacZ/TEF-Fas-d-S1(WEHD)-TA/DTEF3-
Caspase1(C285RG285)-FLAG, (S1,C1(C285RG285)), were trans-
formed with the plasmids encoding the activator Asc, or the
empty vector (-); (B) EGY48-6op-LEU2/2op-lacZ/DTEF2-Fas-d-
S2(DEHD)-TA/DGPD1-HA-Caspase2- FLAG(S2,C2(WT)), EGY48-
6op-LEU2/2op-lacZ/DTEF1-Fas-d- G2(DEHG)-TA/DGPD1-HA-
Caspase2-FLAG (G2,C2(WT)), or EGY48-6op-LEU2/2op-lacZ/
DTEF2-Fas-d-S2(DEHD)-TA/DGPD1-HA-Caspase2(C320RA320)-
FLAG (S2,C2(C320RA320)), were transformed with plasmids
encoding the activator RAIDD, or the empty vector (-); (C) EGY48-
6op-LEU2/2op-lacZ/TEF-Fas-d-S9(LEHD)-TA/TEF-HA-Caspase9
(S9,C9(WT)), EGY48-6op-LEU2/2op-lacZ/TEF-Fas-d-G9(LEHG)-
TA/TEF-HA-Caspase9 (G9,C9(WT)), or EGY48-6op-LEU2/2op-
lacZ/TEF-Fas-d-S9(LEHD)-TA/TEF-HA-Caspase9(C287RA287)
(S9,C9(C287RA287)), were transformed with plasmids encoding an
active form of Apaf-1 (Apaf*), or the empty vector (-); (D) EGY48-
6op-LEU2/2op-lacZ/GPD-Fas-d-S8(LETD)-TA/ADH-Caspase10-
FLAG (S8,C10(WT)), EGY48-6op-LEU2/2op-lacZ/GPD-Fas-d-
G8(LETG)-TA/ADH-Caspase10-FLAG (G8,C10(WT)), or EGY48-
6op-LEU2/2op-lacZ/GPD-Fas-d-S8(LETD)-TA/ADH-Caspase10
(C358RA358)-FLAG (C10(C358RA358)), were transformed with
the plasmids encoding the activator FADD, or the empty vector (-).
The large amount of FADD is enough to activate Caspases-10 by
itself.
Found at: doi:10.1371/journal.pone.0007655.s008 (0.06 MB
PDF)
Figure S7 Specificity of upstream activators of initiator Caspases -
tested by 2-component systems. Yeast transformants were prepared
and tested as described in Figures S5 and S6, except a matrix of
plasmid combinations was prepared to evaluate the specificity of
upstream activators. The substrates and Caspases tested are
indicated across the top, while the activators are indicated along
the side. Note that results obtained were as predicted, with (1) Apaf-
1* activating pro-Caspase-9, but not other initiator Caspases; (2)
RAIDDactivatingpro-Caspase-2,butnototherCaspases;(3)FADD
activating pro-Caspases-8 and 10, but not other Caspases, and (4)
Asc activating pro-Caspase-1 and 8. Note that while Asc contains a
CARD that pairs with a complementary CARD in pro-Caspase-1
and would not be necessarily predicted to activate the DED-
containing protease Caspase-8, it has previously been reported that
Asc is an activator of Caspase-8 (Hasegawa M. et.al. J Biol Chem
280:15122-30 (2005); Masumoto, J. et. al., Biochem. Biophys. Res.
Commun 303: 69-73 (2003). Transformants: Transformed yeast
clones were as follows: S1,C1:EGY48-6op-LEU2/2op-lacZ/TEF-
Fas-d-S1(WEHD)-TA/DTEF3-Caspase1-FLAG; S2,C2:EGY48-
6op-LEU2/2op-lacZ/DTEF2-Fas-d-S2(DEHD)-TA/DGPD1-HA-
Caspase2-FLAG; S8,C8:EGY48-6op-LEU2/2op-lacZ/GPD-Fas-
d-S8/10(LETD)-TA/CYC1-Caspase8-HA; S9,C9:EGY48-6op-
LEU2/2op-lacZ/TEF-Fas-d-S9(LEHD)-TA/TEF-HA-Caspase-9;
S8,C10:EGY48-6op-LEU2/2op-lacZ/GPD-Fas-d-S8/10(LETD)-
TA/ADH-Caspase10- FLAG. These cells were transformed with
the plasmids encoding the activators (Asc, RAIDD, FADD, and
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introduced.
Found at: doi:10.1371/journal.pone.0007655.s009 (0.05 MB
PDF)
Figure S8 Validation of 3-component yeast-based Caspase assay
reconstituting DISC. Yeast transformants were prepared to assess
the performance of the Fas/FADD/Caspase-8/10 three-compo-
nent systems. Two independent clones of each transformant were
plated on leucine-deficient medium containing X-gal. Substrates
included LETD-containing cleavable (S8) and LETG-containing
non-cleavable (G8) transcription factors, while Caspase expression
plasmids included WT pro-Caspases-8 (A) and -10 or a catalytic
mutant of Caspase-10. (B) FADD was expressed at low levels from a
DADH1 promoter. Note that the lacZ reporter gene was activated
only when the combination of Fas, FADD, and either WT pro-
Caspase-8 or -10 was co-expressed and only when a cleavable
substrate (S8) was employed. (Note that the optimal tetrapeptide
cleavage sequence is the same for Caspases-8 and -10). Transfor-
mants: (A) Yeast transformants included EGY48-6op-LEU2/2op-
lacZ/TEF-Fas-d-S8 (LETD)-TA/CYC1-Caspase-8-HA (S8,C8)
EGY48-6op-LEU2/2op-lacZ/TEF-Fas-d-G8(LETG)-TA/CYC1-
Caspase8-HA (G8,C8), without (-) or with Fas, and without (-) or
with FADD, which were expressed from either ADH and DADH1
promoter, respectively, to achieve high expression of Fas and low
expression of FADD. (B) Yeast transformants included: EGY48-
6op-LEU2/2op-lacZ/GPD-Fas-d-S8(LETD)-TA/CYC1-Caspase10-
FLAG (S8,C10); EGY48-6op-LEU2/2op-lacZ/GPD-Fas-d-G8
(LETG)-TA/CYC1-Caspase10-FLAG (G8,C10); and EGY48-
6op-LEU2/2op-lacZ/GPD-Fas-d-S8 (LETD)-TA/CYC1-Caspa-
se10(C358RA358)-FLAG (S8,C10(C358RA358)) each without (-)
or with Fas, and without (-) or with FADD-expressing vector or the
corresponding empty vectors.
Found at: doi:10.1371/journal.pone.0007655.s010 (0.05 MB
PDF)
Figure S9 Flow chart for cDNA library screening using 3
component system - application to death receptor cloning-Example
#1. The screening strategy is essentially the same as outlined in
Figure 3. The yeast transformant EGY48-6op-LEU2/2op-lacZ/
TEF-Fas-d-S8(LETD)-TA/CYC1-Caspase8-HA/DADH1-FADD
was transformed with a HepG2 cell cDNA library (oligo dT-primed,
PADH promoter). Independent colonies (1.76106) appeared on
growth plates within 48 hours. Cells were collected, pooled, and a
portion (2.46107) was seeded on the leucine-deficient selection
plates containing X-gal. Blue-colored colonies (n=150) appeared
within a week, 13 of which encoded DR4, (#XA514), and 15 clones
encodedDR5variant2(#ZA512),whiletherestwerefalsepositives.
Screening another cDNA library from HepG2 cells (random-
primed, PADH promoter) yielded eight DR5 (#XD108) clones.
Found at: doi:10.1371/journal.pone.0007655.s011 (0.05 MB
PDF)
Figure S10 Flow chart for cDNA library screening using 3
component system to clone death receptors - Example #2. The
screening strategy is essentially the same as outlined in Figure 3.
The yeast transformant EGY48-6op-LEU2/2op-lacZ/TEF-Fas-d-
S8(LETD)-TA/CYC1-Caspase8-HA/DADH1-FADD was trans-
formed with a human liver cDNA library (random-primed, PADH
promoter) and a HeLa cell cDNA library (random-primed, PADH
promoter).
Found at: doi:10.1371/journal.pone.0007655.s012 (0.04 MB
PDF)
Figure S11 Flow chart for cDNA library screening using 3-
component system to to clone death receptors - Example #3. The
screening strategy is essentially the same as outlined in Figure 3.
The yeast transformant EGY48-6op-LEU2/2op-lacZ/TEF-Fas-d-
S8(LETD)-TA/CYC1-Caspase8-HA/DADH1-FADD was trans-
formed with a HEK293T cell cDNA library (oligo-dT-primed,
PADH promoter) and a HEK293T cell cDNA library (random-
primed, PADH promoter, HA-tagged).
Found at: doi:10.1371/journal.pone.0007655.s013 (0.04 MB
PDF)
Figure S12 Schematic representation of 3-component system
used for cloning adapter protein that links Fas to pro-Caspase-10.
(A) The zymogen pro-Caspase-10 was expressed (from CYC1-
promoter) with substrate containing the LETD-containing cleav-
age element S8 (from plasmid p413-GPD-Fas-d-S8-TA/CYC1-
Caspase-10-FLAG) in the yeast EGY48 expressing 6op-LEU2. Fas
was also expressed without activating the Caspase-10 from plasmid
p426-2op-lacZ/ADH-Fas. (B) Addition of FADD activates
Caspase-10, releasing the transcription factor.
Found at: doi:10.1371/journal.pone.0007655.s014 (0.04 MB
PDF)
Figure S13 Validation of adapter protein cloning system for
Fas/FADD/Caspase-8/10: Reconstituted DISC. Yeast cell trans-
formants were prepared to assess the performance of the Fas/
FADD/Caspase-8 or Fas/FADD/Caspase-10 three-component
systems. Two independent clones of each transformant were
plated on leucine-deficient medium containing X-gal and grown
for 4 days. Substrates included LETD-containing cleavable (S8)
and LETG-containing non-cleavable (G8) transcription factors,
while Caspase expression plasmids included wild-type (WT) pro-
Caspases-8 (A) and -10 or a catalytic mutant of Caspase-10
(C358RA358) (B). Note that the lacZ reporter gene was activated
only when the combination of Fas, FADD, and either WT pro-
Caspase-8 or -10 was co-expressed and only when a cleavable
substrate (S8) was employed. Transformants: (A) Yeast cell
transformants included: EGY48-6op-LEU2/2op-lacZ/TEF-Fas-
d-S8 (LETD)-TA/CYC1-Caspase8-HA (S8,C8) and EGY48-6op-
LEU2/2op-lacZ/TEF-Fas-d-G8 (LETG)-TA/CYC1-Caspase8-
HA (G8,C8), with empty vector (-) or with plasmids encoding
FADD (expressed from CYC1 promoter) or Fas (expressed from
ADH promoter). (B) Yeast cell transformants included EGY48-
6op-LEU2/2op-lacZ/GPD-Fas-d-S8(LETD)-TA/CYC1-Caspase10-
FLAG (S8,C10), EGY48-6op-LEU2/2op-lacZ/GPD-Fas-d-G8
(LETG)-TA/CYC1-Caspase10-FLAG (G8,C10), and EGY48-
6op-LEU2/2op-lacZ/GPD-Fas-d-S8(LETD)-TA/CYC1-Caspase10
(C358RA358)-FLAG (S8,C10(C358RA358)), each with empty
vector (-) or with plasmids encoding FADD or Fas as above.
Found at: doi:10.1371/journal.pone.0007655.s015 (0.05 MB
PDF)
Figure S14 Flow chart for cDNA library screening using 3
component system to clone adapters. Yeast transformant EGY48-
6op-LEU2/2op-lacZ/GPD-Fas-d-S8(LETD)-TA/ADH-Fas/CYC1-
Caspase10-FLAG wastransformed with a HEK293cellcDNA library
(random-primed, PADH promoter, HA-tagged). Independent colo-
nies (,2.26106) appeared on growth plates within 48 hours. Cells
were collected, pooled, and a portion (3.26107) was seeded on
leucine-deficient selection plates containing X-gal. Blue-colored
colonies (n=200) appeared within a week, five of which encoded
full-length Caspase-2 (#XA227), five encoded a fragment of Caspase-
2( #ZA214), five encoded a fragment of Caspase-8 (#XA221), and 24
encoded full-length FADD (#XA212), while the rest were apparent
false positives.
Found at: doi:10.1371/journal.pone.0007655.s016 (0.03 MB
PDF)
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activated the reporter genes were characterized by recovery of
cDNA library plasmids and retransformation into yeast expressing
Fas and pro-Caspase-10 (A), pro-Caspase-10 without Fas (B), or
neither (C). Among the positive clones were a full-length Caspase-
2( #XA227), a fragment of Caspase-2 (#ZA214, V130-L312), a
fragment of Caspase-8 (#XA221, M1-K438), and full-length
FADD (#XA212). Assays were performed in duplicate, growing
cells for 4 days on plates.
Found at: doi:10.1371/journal.pone.0007655.s017 (0.05 MB
PDF)
Figure S16 Optimization of signal:noise ratio in microtiter
plates: cell density. EGY48 cells containing the 3-component Fas/
FADD/Caspase-8 system and Caspase-8-cleavable reporter were
seeded at 2.356104/well (A), 26105/well (B), or 3.766105/well
(C) in 384 well plates to compare cell densities. Cells were cultured
at 30uC. The activity of b-galactosidase was measured after 72 hrs
at various times after initiating cultures (mean+std dev; n=3), for
cells grown without (white circles) or with (black circles and black
squares) X-gal and grown in the absence (circles) or presence
(black squares) of 100 mM zVAD-fmk Caspase inhibitor.
Found at: doi:10.1371/journal.pone.0007655.s018 (0.04 MB
PDF)
Figure S17 Optimization of signal:noise ratio in microtiter
plates: time and X-gal concentration. (A) EGY48 cells containing
the 3-component Fas/FADD/Caspase-8 system and Caspase-8-
cleavable reporter were grown at 26105 cells/well in 384
well plates, comparing b-galactosidase activity at various times
(mean 6 std dev; n=3), for cells grown in the absence (black
squares) or presence (circles) of X-gal and in the absence (circles) or
presence (squares) of 100 mM zVAD-fmk Caspase inhibitor. (B)
EGY48 cells containing the 3-component NLRP1DLRR/Asc/
Caspase-1 system and Caspase-1-cleavable reporter were grown at
26105 cells/well in 384 well plates, comparing X-gal concentra-
tions. The activity of b-galactosidase was measured after 72 hrs
culture (mean 6 std dev; n=3) for cells grown in the absence (red
circles) or presence (all others) X-gal. Various concentrations of
X-gal were compared.
Found at: doi:10.1371/journal.pone.0007655.s019 (0.04 MB
PDF)
Figure S18 Determination of Z’ scores for NLRP1(NALP1) and
Fas(CD95) 3-component yeast-based HTS assays using caspase
inhibitorzVAD-fmk.(A)Yeaststrain EGY48harboringtheNLRP1/
ASC/Caspase-1 proteolytic network (B) or the Fas/FADD/Caspase-
8 proteolytic network were cultured at 26105 cells/well for 48 hours
in SD media containing 400 mg/ml X-gal with DMSO solvent
control (blue) or zVAD in DMSO (100 mM final concentration)
(purple). The Z’ scores were determined by comparison of the
DMSO-treated samples with the zVAD-treated samples.
Found at: doi:10.1371/journal.pone.0007655.s020 (0.34 MB
PDF)
Figure S19 Experiments with ATG4B-expressing yeast. (A)
Determination of cell density dependence. The production of b-
galactosidase activity (y-axis) in 384 well plate format was compared
for various densities of EGY48 cells (x-axis) harboring plasmids
encoding ATG4B and the LC3-containing substrate and lacZ
reporter genes containing either 2 (red, orange) or 8 (blue, green)
LexA-operators. Medium consisted of 1% galactose/2%raffinos,
with 100 mg/ml X-gal. Cells were cultured at 30uC for 48 hrs, then
absorbance was measured at OD 620 nm. Data represent
mean6std dev (n=4). (B) The time-course of b-galactosidase
activity generation was compared for EGY48 cells containing
plasmids encoding LEU2 and lacZ reporter with (2 vs 8) LexA
operators. Cells were plated and culture as described above. Data
represent mean 6 std dev (n=4).
Found at: doi:10.1371/journal.pone.0007655.s021 (0.02 MB
PDF)
Figure S20 Plasmids for co-expression of Caspases and substrate
cleavable transcription factors in yeast. The plasmid p413 was
used as the backbone for these constructions, containing CEN/
ARS centromeric origin for low-copy episomal replication in yeast
(S. cerevisiae) and HIS3 gene for selection in his3 yeast strains. (A)
The plasmid p413-TEF-Fas-d-S1-TA, where expression of the
Fas-LexA/B42 membrane tethered transcription factor with
WEHD linker (Caspase-1/4/5 cleavable) is driven by the TEF
promoter. (B) The plasmid p413-TEF-Fas-d-S1-TA/DTEF3-
Caspase-1-FLAG, contains two additional transcriptional units,
where expression of the Fas-LexA/B42 membrane tethered
transcription factor with WEHD linker (Caspase-1/4/5 cleavable)
is driven by the TEF promoter and expression of pro-Caspase-1
with C-terminal FLAG tag is driven by an attenuated TEF3
promoter (DTEF3). (C) The plasmid p413-TEF-Fas-d-S8-TA/
CYC1-Caspase-8-HA contains two additional transcriptional
units, where expression of the Fas-LexA/B42 membrane tethered
transcription factor with LETD linker (Caspase-8/10 cleavable) is
driven by the TEF promoter and expression of pro-Caspase-8 with
C-terminal HA tag is driven by CYC1 promoter. (D) The plasmid
p413-GDP-Fas-dS8-TA/CYC1-Caspase-10-FLAG, similarly con-
tains two additional transcriptional units, where expression of the
same Caspase-8/10 cleavable Fas-LexA/B42 substrate as above is
driven by GDP promoter and where expression of pro-Caspase-8
with C-terminal FLAG tag is driven by CYC1 promoter.
Transcriptional termination elements from the CYC1 and ADH
genes were employed as illustrated.
Found at: doi:10.1371/journal.pone.0007655.s022 (0.07 MB
PDF)
Figure S21 Plasmids for expression of upstream activators of
Caspases and lacZ reporter gene in yeast. The plasmid p426 was
used as the backbone for these constructions, containing 2m
plasmid origin for high-copy episomal replication in yeast and
URA3 gene for selection in ura3 yeast strains. (A) The plasmid
p426-2op-lacZ contains a lacZ gene driven by a minimal promoter
containing two tandem copies of binding sites for the LexA
transcription factor, followed by ADH gene termination element.
(B) Plasmid p426-2op-lacZ/CYC1-HA-Asc contains an additional
transcriptional unit, where expression of human cDNA encoding
N-terminal HA-tagged Asc protein is driven by a CYC1 promoter,
and followed by ADH gene termination element. (C) In plasmid
p426-2op-lacZ/DADH1-FADD, expression of a human FADD
cDNA is driven by DADH1 promoter and followed by ADH
termination element. (D) Plasmid p426-2op-lacZ/ADH-Fas con-
tains a human Fas(CD95) cDNA driven by ADH promoter, and
followed by CYC1 gene termination element.
Found at: doi:10.1371/journal.pone.0007655.s023 (0.05 MB
PDF)
Figure S22 Yeast expression plasmids for functional screening of
cDNA libraries and expression of upstream activators of Caspases.
The plasmid p424 was used as the backbone for these
constructions, containing 2m plasmid origin for high-copy episomal
replication in yeast (S. cerevisiae) and TRP1 gene for selection in
trp1 yeast strains. (A) The plasmid p426-GAL1-cDNAs contains
human cDNAs directionally cloned downstream of a GAL1
promoter, followed by CYC1 gene termination element. (B)
Plasmid p424-CYC1-HA-Asc contains a human cDNA encoding
N-terminal HA-tagged Asc protein cloned downstream of a CYC1
Yeast-Based Protease Technlgys
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plasmid p424-CYC1-HA-Asc/TEF-NLRP1DLRR, an additional
transcriptional unit was added to p424-CYC1-HA-Asc above,
where expression of a human cDNA encoding a gain-of-function
NLRP1 mutant lacking LRRs (Faustin, B, et al. Molecular Cell
25;713, 2007) is driven by a TEF promoter and followed by ADH
gene termination element.
Found at: doi:10.1371/journal.pone.0007655.s024 (0.04 MB
PDF)
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